BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak is a pharma and life sciences industry update from PharmaVoice. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

PharmaVoice staff · 2026-06-05

While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease

Source: PharmaVoice